Yu-Wei Chen Taiwan

Yu-Wei Chen
Dr. Tim Yu-Wei Chen is a nephrologist and an intensivist at Taipei Medical University–Shuang Ho Hospital, Taiwan. He received his M.D. from Taipei Medical University and has recently obtained his Ph.D. in the Graduate Institute of Clinical Medicine at Taipei Medical University. He completed his residency training in Internal Medicine and fellowship in Nephrology at Taipei Veterans General Hospital before joining Shuang Ho Hospital as an attending physician in 2015. He has been a visiting scholar at the University of Southern California from 2023 to 2025. He now serves as a clinical faculty member at the College of Medicine, Taipei Medical University, where he is actively involved in undergraduate and postgraduate medical education. Dr. Chen specializes in nephrology and critical care medicine, with particular expertise in acute kidney injury (AKI), acute kidney disease (AKD), continuous kidney replacement therapy (CKRT/CRRT), extracorporeal blood purification, sepsis-associated AKI, electrolyte and acid-base disorders, and critical care nephrology. As the nephrologist who is responsible for critical care nephrology, he leads multidisciplinary teams caring for critically ill patients requiring advanced organ support and kidney replacement therapies. His research focuses on acute kidney injury, critical care nephrology, kidney replacement therapy, and the development of digitalized clinical decision support systems. Dr. Chen also conducted translational research about peritoneal dialysis, delineating the association of physical stimuli and peritoneal fibrosis. He has participated in numerous investigator-initiated clinical trials and translational research projects and has presented his work at major international meetings, including the Taiwan Society of Nephrology (TSN) and the American Society of Nephrology (ASN). Beyond his clinical and research activities, Dr. Chen enjoys engaging diverse audiences and communicating complex medical concepts with clarity, enthusiasm, and professionalism. His experience in public speaking, teaching, and international collaboration has made him a confident and dynamic communicator both on the conference stage and in academic settings. Dr. Chen has authored and co-authored more than 15 peer-reviewed publications in the fields of nephrology, acute kidney injury, and peritoneal dialysis. His ongoing work aims to bridge clinical practice, biomedical innovation, and digital health technologies to improve outcomes for patients with kidney diseases worldwide.

18th September 2026 Friday

Time Session
08:00
12:30
Acute PD Lecture
(Pre-Congress Workshop)
  • Opening & Workshop Orientation
    Chih-Hsiang ChangTaiwan Speaker 重塑生命韌性：從 ICU 治療到回歸社會的康復之路急性腎損傷的照護目標不應止於 ICU 存活或成功脫離連續性腎臟替代治療（CRRT），而應延伸至腎功能恢復、身體功能重建與重返家庭及社會。高品質 CRRT 是此一照護路徑的起點，包括適切的治療時機與劑量、血流動力學穩定、液體管理、抗凝策略及治療中斷監測，以降低治療相關傷害並提升腎臟恢復機會。然而，出院後追蹤中斷、急性腎損傷病程辨識不足及跨專業資訊斷裂，仍使患者面臨慢性腎臟病、長期透析、再住院及功能衰退的風險。因此，台灣應建立從 ICU 延伸至社區的急性腎損傷整合照護政策：以標準化品質指標確保 CRRT 治療品質；透過電子警示、風險分層與跨院資料串接辨識高風險患者；並於出院後整合腎臟功能、藥物、營養、復健及病人報告結果的追蹤。最終政策成效不僅應評估死亡率與透析依賴，更應納入腎功能恢復、再住院、生活品質及重返社會，將急性期救命治療轉化為可衡量、可持續的生命韌性照護。
  • Acute PD in AKI: Why, When, and How?
    Mu-Chi ChungTaiwan Speaker Acute PD in AKI: Why, When, and How?
    Chih-Ching LinTaiwan Moderator
    Ching-Chung HsiaoTaiwan Moderator
  • Initiating Acute PD in the ICU: What Actually Works in Practice
    Yu-Wei ChenTaiwan Speaker Initiating Acute PD in the ICU: What Actually Works in Practice
    Chih-Ching LinTaiwan Moderator
    Ching-Chung HsiaoTaiwan Moderator
  • Case-Based Demonstration and Discussion
    Hsuan-Jen LinTaiwan Speaker Case-Based Demonstration and DiscussionPrescription Design and Adjustment Exercises (Case-based discussion)Troubleshooting Common ICU Problems (Case-based discussion)
    Chih-Ching LinTaiwan Moderator
    Ching-Chung HsiaoTaiwan Moderator
  • Coffee Break
  • Acute PD: Physiology, Prescription, and Technique (Surgical vs Percutaneous Implantation)
    Che-Yi ChouTaiwan Speaker Acute PD: Physiology, Prescription, and Technique (Surgical vs Percutaneous Implantation)Acute peritoneal dialysis (PD) is an effective, underutilized method for treating acute kidney injury through optimized, high-volume automated regimens. While percutaneous bedside insertion offers rapid, resource-efficient access for critically ill patients, surgical techniques provide better visualization and lower early leak rates.Prescription Design and Adjustment Exercises (Case-based discussion)This interactive, case-based discussion session focuses on the practical application of peritoneal dialysis (PD) prescription design and dynamic troubleshooting. Clinical practitioners often face challenges when translating standard PD guidelines into individualized patient care, particularly when balancing solute clearance, ultrafiltration goals, and patient lifestyle preferences. Utilizing a series of real-world patient scenarios, this session guides participants through the step-by-step process of calculating initial automated PD (APD) and continuous ambulatory PD (CAPD) prescriptions based on residual renal function and peritoneal membrane transport characteristics. Participants will actively analyze clinical data from cases demonstrating inadequate clearance, fluid overload, and metabolic complications. Through hands-on exercises, attendees will learn to systematically adjust dwell times, exchange volumes, and dextrose concentrations to optimize therapy. By the conclusion of this session, participants will possess the critical thinking skills necessary to confidently manipulate PD prescription variables, manage common prescription failures, and improve long-term patient outcomes.Troubleshooting Common ICU Problems (Case-based discussion) This interactive, case-based discussion session addresses the rapid identification and management of critical mechanical, metabolic, and infectious complications in the intensive care unit. Using realistic patient scenarios, clinicians will practice troubleshooting ventilator dyssynchrony, hemodynamic instability, continuous renal replacement therapy (CRRT) circuit alarms, and acute metabolic crises. Through hands-on exercises, participants will interpret real-time clinical data, isolate root causes, and execute immediate corrective interventions. This session equips multidisciplinary ICU teams with the critical thinking skills, diagnostic algorithms, and collaborative strategies necessary to resolve technical failures promptly and improve patient outcomes in high-stress environments.
    Ben-Chung ChengTaiwan Moderator
    Wei-Cheng TsengTaiwan Moderator
  • Complication Management in Acute PD (UF Failure, Acidosis, Lytes, Peritonitis)
    Yu-Cyuan HongTaiwan Speaker Complication Management in Acute PD (UF Failure, Acidosis, Lytes, Peritonitis)Acute peritoneal dialysis remains a practical option for AKI when hemodynamic instability, coagulopathy, absent vascular access, or resource constraints limit extracorporeal therapy. Its complication profile, however, differs from that of chronic PD: the catheter is freshly placed, the membrane is acutely inflamed and often high-transport, exchanges are rapid and hypertonic. First, inadequate ultrafiltration is separated into mechanical causes (catheter malposition, omental wrap, leak to pleural or subcutaneous tracking) and membrane-prescription causes. Management follows from that division — imaging and repositioning, or shortened dwell and adjusted tonicity — rather than reflexive escalation of dextrose concentration. Electrolyte complications follow directly from the prescription: hypokalemia from potassium-free dialysate compounded by glucose-driven intracellular shift; hypernatremia from sodium sieving during short hypertonic dwells; Peritonitis in acute PD differs from its chronic counterpart. Risk is front-loaded by bedside insertion, immediate use, and repeated manual exchanges, so prevention rests on closed connectology, cycling, and minimal manipulation. Short dwells dilute the effluent cell count, making neutrophil percentage more reliable than the absolute number; in a sedated septic patient the first sign may be falling ultrafiltration.
    Ben-Chung ChengTaiwan Moderator
    Wei-Cheng TsengTaiwan Moderator
  • Integration of Acute PD into AKI Programs
    Chia-Lin WuTaiwan Speaker Integration of Acute PD into AKI ProgramsAcute kidney injury (AKI) affects 30–60% of critically ill patients, and dialysis-requiring AKI carries substantial short-term mortality and long-term risk of chronic kidney disease. While continuous renal replacement therapy and intermittent hemodialysis remain the default modalities in most high-income ICUs, acute peritoneal dialysis (PD) has re-emerged as a guideline-supported, outcome-comparable alternative—particularly valuable when vascular access, anticoagulation, or extracorporeal capacity are limited. The 2020 ISPD guideline update has standardized safe prescribing, and the COVID-19 pandemic demonstrated that acute PD programs can be stood up rapidly under pressure, with outcomes consistent with standard care. This presentation argues that the principal barriers to integrating acute PD into AKI programs are not clinical but organizational. Drawing on international literature and regional case experience, it presents a practical framework for building a program: catheter access and prescription fundamentals; a genuine nephrology–intensivist–nursing collaborative model with defined roles and governance; structured training pathways for catheter insertion and bedside nursing delivery, including simulation-based approaches used in low-resource settings; logistics planning for supply chains, staffing, and cost; and strategies for overcoming institutional barriers such as credentialing, reimbursement, and clinician culture.
    Ben-Chung ChengTaiwan Moderator
    Wei-Cheng TsengTaiwan Moderator
  • Closing
    Ben-Chung ChengTaiwan Speaker
Room 101C
18:00
19:00
Mini‑Oral Presentation 1 - Group C
Shotaro MatsumotoJapan Moderator The Ultimate Support: Heart-Lung-Kidney Crosstalk and ECMO-CRRT Integration in PediatricsExtracorporeal membrane oxygenation (ECMO) and continuous kidney replacement therapy (CKRT) support pediatric cardiopulmonary failure complicated by acute kidney injury (AKI) and fluid overload (FO). AKI and multiorgan dysfunction are increasingly viewed through bidirectional kidney-lung-heart crosstalk, extending in ECMO/CKRT patients to artificial organs: oxygenator, blood pump, and hemofilter. Kidney-lung crosstalk shares pathways of vascular rigidity, neurohormonal activation, tissue hypoxia, and aberrant immune signaling. Ventilator-induced biotrauma impairs renal function, while AKI worsens lung injury via fluid, acid-base, and cytokine derangements; positive-pressure ventilation further raises right-ventricular afterload and central venous pressure, reducing renal perfusion. Kidney-heart crosstalk (cardiorenal syndrome type 3) involves analogous inflammatory and neuroendocrine mechanisms and carries a high mortality risk in children. Beyond native organs, the oxygenator activates complement/inflammatory cascades via blood-biomaterial contact, and non-pulsatile pump flow causes shear-induced hemolysis, with free hemoglobin/iron contributing to AKI. CKRT-ECMO circuit connection requires attention to circuit pressures, embolism risk, and altered drug pharmacokinetics-challenges framed by the multiple organ support therapy (MOST) concept. Key management priorities include early correction of FO, standardized CKRT-ECMO integration per PCRRT-ICONIC and ADQI/ELSO consensus recommendations, lung-protective ventilation and conservative fluid management, and long-term renal/blood-pressure surveillance after ECMO. Research has evolved from single-center FO-mortality studies to consensus statements, the extracorporeal organ support concept, and the multicenter WE-ROCK registry, with recent work clarifying molecular mechanisms of sepsis-associated lung-kidney crosstalk. Future work should pursue biomarker-driven endotyping and integrated MOST platforms.Core Decisions: Modality Selection (CVVH / CVVHD / CVVHDF) & PrescriptionModality selection and dose prescription remain unresolved in pediatric continuous kidney replacement therapy (CKRT). Pediatric trials are scarce, so practice extrapolates from adult evidence, while 2026 KDIGO and Surviving Sepsis Campaign updates have reopened debate. Ronco's 2000 trial established an "at least 35 mL/kg/h" paradigm after showing improved survival with higher ultrafiltration, later refuted by the large ATN and RENAL trials, which found no survival benefit from higher intensity and more complications. KDIGO 2012 therefore recommended a delivered dose of 20-25 mL/kg/h, unchanged in the 2026 draft, which additionally now recommends against high-volume hemofiltration (HVHF) in adult septic AKI, reflecting negative IVOIRE trial and Cochrane review findings. For modality, CVVHDF has become dominant in the WE-ROCK pediatric registry, rising from 30% to 76% of prescriptions, though some favor CVVH for convective clearance; no modality shows a survival advantage. For dose, the 2026 KDIGO draft newly defines pediatric practice points: weight- rather than surface-area-based prescription to avoid inadvertent infant overdosing, initial effluent of 25-30 mL/kg/h, augmented dosing to 200 mL/kg/h for hyperammonemia, and an ultrafiltration-rate of maximal 2.5ml/kg/h. WE-ROCK data show prescribed doses far exceeding these targets without an observed dose-outcome association. Adding to this uncertainty, the 2026 pediatric Surviving Sepsis Campaign guideline newly recommends HVHF (>35 mL/kg/h) in septic shock, conditionally and with low certainty, reversing its 2020 position on a fragile three-trial meta-analysis (Fragility Index=1)-contrasting with adult evidence and the concurrent adult KDIGO recommendation against HVHF. Given risks such as dialytrauma and drug underdosing, this fragile signal warrants cautious application. This session invites participants to weigh this evidence and build a practical framework for individualizing modality and dose decisions at the bedside.
Yu-Wei ChenTaiwan Moderator Initiating Acute PD in the ICU: What Actually Works in Practice
Room 101D

19th September 2026 Saturday

Time Session
18:00
19:00
Mini‑Oral Presentation 2 - Group D
Nuttha LumlertgulThailand Moderator Solution and Fluid BalanceUtility of Lung Ultrasound, VEXUS and Bioimpedance Analysis in Volume Assessment During RRTPersonalized Fluid Management with CRRT
Ting-Yu ChiouTaiwan Moderator
Room 103

20th September 2026 Sunday

Time Session
12:40
13:45
Lunch Symposium 6- Fresenius Kabi
Ming-Cheng ChanTaiwan Moderator
Yi-Wen ChiuTaiwan Moderator
  • Opening
  • Mind the Gap: Optimizing Nutrition in Critically Ill Patients with AKI
    Yu-Wei ChenTaiwan Speaker Initiating Acute PD in the ICU: What Actually Works in Practice
  • Protecting the Kidney with Amino Acids: Translating the PROTECTION Trial into Cardiac Surgery Practice in Taiwan
    Chih-Hsiang ChangTaiwan Speaker 重塑生命韌性：從 ICU 治療到回歸社會的康復之路急性腎損傷的照護目標不應止於 ICU 存活或成功脫離連續性腎臟替代治療（CRRT），而應延伸至腎功能恢復、身體功能重建與重返家庭及社會。高品質 CRRT 是此一照護路徑的起點，包括適切的治療時機與劑量、血流動力學穩定、液體管理、抗凝策略及治療中斷監測，以降低治療相關傷害並提升腎臟恢復機會。然而，出院後追蹤中斷、急性腎損傷病程辨識不足及跨專業資訊斷裂，仍使患者面臨慢性腎臟病、長期透析、再住院及功能衰退的風險。因此，台灣應建立從 ICU 延伸至社區的急性腎損傷整合照護政策：以標準化品質指標確保 CRRT 治療品質；透過電子警示、風險分層與跨院資料串接辨識高風險患者；並於出院後整合腎臟功能、藥物、營養、復健及病人報告結果的追蹤。最終政策成效不僅應評估死亡率與透析依賴，更應納入腎功能恢復、再住院、生活品質及重返社會，將急性期救命治療轉化為可衡量、可持續的生命韌性照護。
  • Q & A
Room 101AB